Als donateur kunt u ook korting krijgen bij verschillende bedrijven: 

https://kanker-actueel.nl/NL/voordelen-van-ops-lidmaatschap-op-een-rijtje-gezet-inclusief-hoe-het-kookboek-en-de-recepten-op-basis-van-uitgangspunten-van-houtsmullerdieet-te-downloaden-enof-in-te-zien.html

31 januari 2019: lees ook dit artikel: 

https://kanker-actueel.nl/tcm-traditionele-chinese-medicijnen-kruiden-verbeteren-ziektevrije-tijd-met-15-procent-voor-operabele-darmkanker-stadium-iii-in-vergelijking-met-geen-tcm-darmtumoren-aan-linkerkant-hadden-beste-ziektevrije-tijd-56-vs-42-procent-voor-geen-tcm.html

13 november 2015: Bron: Journal of Chinese Integrative Medicine.

Wanneer darmkankerpatiënten na een operatie aanvullend of bij ouderen ook alleen TCM - Traditionele Chinese Medicijnen krijgen vermindert daarmee het risico op het krijgen van een recidief binnen 5 jaar met respectievelijk 39%, 39% en 15% en in vergelijking met alleen een westerse aanpak van chemo en/of bestraling na operatie.Dit blijkt uit drie gerandomiseerde studies bij respectievelijk, 222 patienten, 366 patienten en 78 patienten, allemaal met operabele darmkanker stadium II en III.

Als mensen mij informatie vragen over darmkanker, meestal in een later stadium  maar toch dan adviseer ik hun altijd minimaal chemosupport en / of radiosupport te bestellen bij de natuurapotheek om de bijwerkingen te verminderen en hopelijk de effectiviteit van de chemo c.q. bestraling te verbeteren. Deze drie studies bewijzen dat dit dus een prima advies is. Mocht u willen weten wat er in chemosupport zit dan kan ik u wel een PDF file sturen met de samenstelling van zowel radiosupport als chemosupport. Chemosupport en radiosupport(3) (red: Voor alle duidelijkheid ik/wij hebben geen enkel belang, noch financieel noch in welke andere vorm dan ook, bij deze verwijzing naar de natuurapotheek).

TCM beeld kruiden 3

Foto: enkele Chinese kruiden, maar sommige TCM kruiden worden ook per infuus ingebracht

Hier de resultaten uit de drie studies:

In een studie met 78 oudere patiënten met operabele darmkanker stadium II en III bleek dat op de 5-jaars meting de ziektevrije tijd, dus klinisch kankervrij, een verschil te zien gaf van 29,6% voor de westerse aanpak versus 74,6% voor de TCM groep of zolas de chinezen dat noemen Traditional Chinese Medicine Syndromedifferentation and treatment.

Resultaten:

There was significant difference between the two groups (P=0.012). The 1-, 2-, 3-, 4-, and 5-year DFS rates of Western medicine group were 87.7%, 69.6%, 63.4%, 46.5%, and 29.6%, respectively. The 1-, 2-, 3-, 4-, and 5-year DFS rates of integrated therapy group were 100%, 86.3%, 74.6%, 74.6%, and 74.6%, respectively.

In een studie met 222 patiënten (202 evalueerbaar) met operabele darmkanker stadium II en III bleek het verschil in de kans op het krijgen van een recidief binnen 5 jaar 15 procent: 21.28% (10 uit 47) voor de TCM groep plus westerse aanpak (N=98) versus 38.18%(21/55) voor alleen met de westerse aanpak (N=104). Mediaan bleek de tijd als zich een recidief voordeed na 26,5 maanden voor de TCM groep plus westerse aanpak versus 16 maanden voor alleen de westerse aanpak.

Resultaten:

The relapse/metastasis rate of 1-, 2-, 3-, 4-, and 5-year were 0 (0/98), 2.04% (2/98), 11.69% (9/77), 14.06% (9/64), and 21.28% (10/47) in the combined group, and were 4.80%(5/104), 16.35% (17/104), 21.65% (21/97), 25.93% (21/81), and 38.18%(21/55) in the WM group, respectively. A significant difference was found in the second year between the two groups (χ 2=12.117, P=0.000). Median relapse/metastasis time was 26.5 months in the combined group and 16.0 months in the WM group.

In een studie met 366 patiënten met operabele darmkanker stadium III bleek het verschil in de kans op het krijgen van een recidief binnen 5 jaar 39%: 59% bleek op 5 jaar nog steeds ziektevrij voor TCM plus chemogroep versus 20% voor alleen chemo:

Resultaten:

The recurrence or metastasis occurred in 145 cases (39. 61%) of the 366 patients. Of them, local recurrence occurred in 17 cases (11.72%), liver metastasis in 45 cases (31.03%), lung metastasis in 52 cases (35.86%), and metastasis in other parts in 53 cases (36.55%). Results of one-factor analysis showed six factors such as the tumor location, pathological type, staging of clinical pathology, chemotherapeutic cycle, radiotherapy, and CMM treatment were correlated with the DFS, showing statistical difference (P<0.01, P<0.05). Results of multifactor analysis showed staging of clinical pathology, chemotherapeutic cycle, and CMM treatment were correlated with the DFS, showing statistical difference (P<0.01). Results of stratified study on the staging of clinical pathology indicated that the primary tumor location (P=0.016) and the pathological type (P=0.047) were the independent predictors for DFS of stage II CC. The median DFS of the two groups could not be calculated. Results of stratified study on the stages of clinical pathology indicated that CMM treatment (P=0.000) and chemotherapeutic cycle (P=0.017) were independent predictors for DFS of stage III CC. As for comparing the composition ratio of the two therapeutic cycles, results showed the baselines of the chemotherapeutic cycle of the two groups were balanced. Further comparison showed the median DFS for the chemotherapy group at stage III was 24. 16 months, while it could not be calculated in the combination group. The DFS, 1-, 2-, 3-, and 5-year DFS ratios were 92%, 72%, 61%, and 59%, respectively in the stage III CC combination group, while they were 74%, 50%, 36%, and 20%, respectively in the stage IlI CC chemotherapy group.

De abstracten van genoemde drie studies staan hieronder. Volledige studierapproten zijn in het Chinmees dus heeft weinig zin die hier te plaatsen:

TCM syndrome differentiation and treatment is important for improving the prognosis of stage II or III colorectal cancer in elderly patients. Integrated treatment shows benefit for reducing relapse and metastasis rates, and prolonging survival for elderly patients.

Zhong Xi Yi Jie He Xue Bao. 2010 Dec;8(12):1159-64.

[Clinical study on survival benefit for elderly patients with resected stage II or III colorectal cancer based on traditional Chinese medicine syndrome differentiation and treatment].

[Article in Chinese]

Abstract

BACKGROUND:

The incidence of colorectal cancer is high among the elderly. Traditional Chinese medicine (TCM) has been widely used in the treatment for colorectal cancer of old people. However, controlled trials with large sample size evaluating the effect of TCM are rare.

OBJECTIVE:

This research aimed to evaluate the survival benefit of using TCM syndrome differentiation treatment for elderly patients with stage II or III colorectal cancer.

DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS:

A total of 78 patients over 70 with resected stage II or III colorectal cancer were selected from the First Department of Oncology, Longhua Hospital of Shanghai University of Traditional Chinese Medicine, and Department of Anorectal Surgery, Changhai Hospital of Second Military Medical University. Patients were assigned to either integrated treatment group or Western medicine group by their own wills.

MAIN OUTCOME MEASURES:

Cox regression analysis was performed to determine all the potential factors which may affect prognosis such as gender, primary site, pathological type, TNM stage, chemotherapy period, radiotherapy and TCM therapy.

RESULTS:

A total of 78 cases were included in this study with 37 cases in integrated treatment group and 41 cases in Western medicine group. Cox regression analysis suggested that the TNM stage (P=0.001) and TCM therapy (P=0.021) were independent prognostic factors. The hazard ratio [Exp(β)] of TCM therapy was 0.393, and 95% confidence interval (CI) was 0.178-0.870. Median disease-free survival (DFS) of Western medicine group was 41.293 months. DFS of integrated treatment group did not reach the median at the time of analysis. There was significant difference between the two groups (P=0.012). The 1-, 2-, 3-, 4-, and 5-year DFS rates of Western medicine group were 87.7 %, 69.6%, 63.4%, 46.5%, and 29.6%, respectively. The 1-, 2-, 3-, 4-, and 5-year DFS rates of integrated therapy group were 100%, 86.3%, 74.6%, 74.6%, and 74.6%, respectively.

CONCLUSION:

TCM syndrome differentiation and treatment is important for improving the prognosis of stage II or III colorectal cancer in elderly patients. Integrated treatment shows benefit for reducing relapse and metastasis rates, and prolonging survival for elderly patients. The influence of integrated treatment needs to be further evaluated.

PMID:
21144459
[PubMed - indexed for MEDLINE]
References
1. Lai YX, Jing DD. Current status in research of epidemic factors for colorectal cancer[J]. Zhongguo Zhong Liu, 2007, 16(5) : 323-326. Chinese with abstract in English.
  
2. Yu JP. Progress of diagnosis and treatment in colorectal cancer of old people[J]. Liaoning Yi Xue Za Zhi, 1999, 13(5) : 227-229. Chinese.
  
3. Chinese Anti-cancer Association. New criteria for diagnosis and treatment of common malignant tumors (fascicle of colorectal cancer)[M]. Beijing: Peking Union Medical College Press, 1999. 117-139. Chinese.
4. State Bureau of Technical and Quality Supervision. Clinic terminology of traditional Chinese medical diagnosis and treatment — Syndromes[M]. Beijing: Standards Press of China, 1997. 1-3. Chinese.
5. Ministry of Health of the People’s Republic of China. Guidelines for clinical research on Chinese new herbal medicines[M]. Beijing: China Medical Science and Technology Press, 1997. 82. Chinese.
6. Liang Y, Liang YH, Li QF, Zhang L, Yuan X. Correlation analysis of colorectal cancer morbidity at different ages[J]. Xinan Guo Fang Yi Yao, 2004, 14(5) : 574. Chinese.
  
7. O’Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T, Haller DG, Sargent DJ. Survival following recurrence in stageⅡ and Ⅲ colon cancer: findings from the ACCENT data set[J]. J Clin Oncol, 2008, 26(14) : 2336-2341.
    
8. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer[J]. J Clin Oncol, 2006, 24(25) : 4085-4091.
    
9. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Khne CH. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials[J]. Ann Oncol, 2004, 15(9) : 1330-1338.
    
10. Haller DG, Cassidy J, Tabernero J, Maroun JA, De Braud FG, Price TJ, Van Cutsem E, Hill M, Gilberg F, Schmoll H. Efficacy findings from a randomized phase Ⅲ trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage Ⅲ colon cancer (NO16968): Impact of age on disease-free survival (DFS)[J]. J Clin Oncol, 2010, 28(15s) : 3521.
  
11. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging[J]. J Natl Cancer Inst, 2004, 96(19) : 1420-1425.
    
12. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients[J]. N Engl J Med, 2001, 345(15) : 1091-1097.
    
13. Ge JZ, Yang YF, Xu Y, Liang BY, Luo L, Wu Y, Wu XW, Liu DQ, Zhang X, Song FX, Geng ZY. Clinical research of relapse and metastasis of elderly patients with resected colorectal cancer using integrated traditional Chinese and Western medicine[J]. Zhongguo Lao Nian Yi Xue Za Zhi, 2009, 29(1) : 73-76. Chinese.
  
14. Qiu JX, Tang LD. Impact of Chinese herbs with effect of invigorating spleen and nourishing kidney on the multi-stage theory of cancer initiation and starting[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 1993, 8(5) : 16-19. Chinese.
  
   
This article has been cited by other articles ( Within JCIM & JIM )
1. How to appropriately choose and arrange research factors. 2011, 9(4)
2. How to appropriately choose observed indexes. 2011, 9(5)

Chinese Materi Medica - TCM combined chemotherapy could prolong the DFS of stage III CC patients after radical cure.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Sep;32(9):1166-70.

[Effect of Chinese materia medica combined chemotherapy on the survivals of stage II and III colorectal cancer].

[Article in Chinese]

Abstract

OBJECTIVE:

To study the effects of Chinese materia medica (CMM) combined chemotherapy on the recurrence, metastasis, and the disease free survival (DFS) of stage II and III colorectal cancer (CC) patients after radical cure.

METHODS:

Recruited were 366 inpatients and outpatients with stage II and III colorectal cancer (CC) from Changhai Hospital, Second Military Medical University, and Tumor Department of Longhua Hospital, Shanghai University of Traditional Chinese Medicine from January 2002 to December 2008. A non-randomized concurrent control method was adopted. Patients were assigned to the combination group (treated by CMM + chemotherapy, 189 cases) and the chemotherapy group (177 cases) according to whether they were willing to receive the CMM treatment for more than 6 successive months. By using follow-ups at clinics, by letter, and by telephone, the DFS, 1-, 2-, 3-, and 5-year DFS ratios were observed. The correlations between DFS and the gender, age, tumor location, staging of clinical pathology, pathological type, chemotherapeutic cycle, radiotherapy, CMM treatment, end point event (recurrence and metastasis) were analyzed.

RESULTS:

The recurrence or metastasis occurred in 145 cases (39. 61%) of the 366 patients. Of them, local recurrence occurred in 17 cases (11.72%), liver metastasis in 45 cases (31.03%), lung metastasis in 52 cases (35.86%), and metastasis in other parts in 53 cases (36.55%). Results of one-factor analysis showed six factors such as the tumor location, pathological type, staging of clinical pathology, chemotherapeutic cycle, radiotherapy, and CMM treatment were correlated with the DFS, showing statistical difference (P<0.01, P<0.05). Results of multifactor analysis showed staging of clinical pathology, chemotherapeutic cycle, and CMM treatment were correlated with the DFS, showing statistical difference (P<0.01). Results of stratified study on the staging of clinical pathology indicated that the primary tumor location (P=0.016) and the pathological type (P=0.047) were the independent predictors for DFS of stage II CC. The median DFS of the two groups could not be calculated. Results of stratified study on the stages of clinical pathology indicated that CMM treatment (P=0.000) and chemotherapeutic cycle (P=0.017) were independent predictors for DFS of stage III CC. As for comparing the composition ratio of the two therapeutic cycles, results showed the baselines of the chemotherapeutic cycle of the two groups were balanced. Further comparison showed the median DFS for the chemotherapy group at stage III was 24. 16 months, while it could not be calculated in the combination group. The DFS, 1-, 2-, 3-, and 5-year DFS ratios were 92%, 72%, 61%, and 59%, respectively in the stage III CC combination group, while they were 74%, 50%, 36%, and 20%, respectively in the stage IlI CC chemotherapy group.

CONCLUSION:

CMM combined chemotherapy could prolong the DFS of stage III CC patients after radical cure.

PMID:
23185751
[PubMed - indexed for MEDLINE]

The combined therapy of TCM - Traditional Chinese Medicine and Western Medicine - WM may have great clinical value and a potential for decreasing the relapse or metastasis rate in stage II and III colorectal cancer after conventional Western Medicine therapy.

Chin J Integr Med. 2008 Dec;14(4):251-6. doi: 10.1007/s11655-008-0251-9. Epub 2008 Dec 12.

Cohort study on the effect of a combined treatment of traditional Chinese medicine and Western medicine on the relapse and metastasis of 222 patients with stage II and III colorectal cancer after radical operation.

Abstract

OBJECTIVE:

To evaluate the effectiveness of a comprehensive therapy of traditional Chinese medicine (TCM) in reducing the relapse and metastasis of stage II and III colorectal cancer based on conventional Western medicine (WM) therapy.

METHODS:

Two hundred and twenty-two patients in total, diagnosed as stage II and III colorectal cancer from February 2000 to March 2006, were recruited from Xiyuan Hospital, China Academy of Chinese Medical Sciences and the General Hospital of Beijing Military Area. They were followed-up once every 3-6 months. Twenty cases dropped out from the cohort. The remaining 202 patients were all treated with routine WM treatment [including R0 radical operation, or chemotherapy or/and radiotherapy according to national comprehensive cancer network (NCCN) clinical guidelines]. These patients were assigned to two groups based on whether or not they were additionally treated with TCM comprehensive therapy (orally administered with a decoction according to syndrome differentiation, combined with a traditional patent drug over one year). Ninety-eight patients from Xiyuan Hospital were treated with WM and TCM (combined group), and 104 patients from the General Hospital of Beijing Military Area were treated with WM alone (WM group). The demographic data at baseline were comparable, including the operation times, age, sex, TNM staging, and pathological types. The patients were followed-up for one to five years. Up to now, there are 98, 98, 77, 64, and 47 patients with 1, 2, 3, 4, and 5 years of follow-up in the combined group, respectively; and 104, 104, 97, 81, and 55 patients in the WM group, respectively. The results of the 5-year follow-up of all the patients will be available in 2011.

RESULTS:

The relapse/metastasis rate of 1-, 2-, 3-, 4-, and 5-year were 0 (0/98), 2.04% (2/98), 11.69% (9/77), 14.06% (9/64), and 21.28% (10/47) in the combined group, and were 4.80%(5/104), 16.35% (17/104), 21.65% (21/97), 25.93% (21/81), and 38.18%(21/55) in the WM group, respectively. A significant difference was found in the second year between the two groups (chi (2)=12.117, P=0.000). Median relapse/metastasis time was 26.5 months in the combined group and 16.0 months in the WM group.

CONCLUSION:

The combined therapy of TCM and WM may have great clinical value and a potential for decreasing the relapse or metastasis rate in stage II and III colorectal cancer after conventional WM therapy.

PMID:
19082795
[PubMed - indexed for MEDLINE]
References:
  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.PubMed
  2. 2.
    National Cancer Prevention and Control Research Office, Information Statistics Center of Ministry of Health. Monitoring Chinese cities, counties cancer incidence and death. Beijing: China Medical Science and Technology Publishing House, 2002:24–34.
  3. 3.
    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420–1425.PubMedCrossRef
  4. 4.
    Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin 2006;56:160–167.PubMedCrossRef
  5. 5.
    Liu J, Wang WP, Zhou PY, et al. Observation on therapeutic effect of Jianpi Huoxue herbs combined with chemotherapy in treating post-operational colonic cancer patients. Chin J Integr Tradit West Med (Chin) 2005;25(3):207–209.
  6. 6.
    National Cancer Prevention and Control Research Office, Chinese Anti-cancer Association. Diagnosis standard of common malignant tumor in China. Vol 3. Colorectal carcinoma. Beijing: Peking Medical University and Peking Union Medical College United Publishing House, 1990:2–23.
  7. 7.
    Sun Y, Zhou JC, ed. Manual of clinical oncology of internal medicine. 4th ed. Beijing: People’s Medical Publishing House, 2003:337–339.
  8. 8.
    Hua JD, ed. Cancer surgery. Beijing: People’s Military Medical Press,1995:463.
  9. 9.
    Dong ZW, Gu XZ, ed. Clinical oncology. Beijing: People’s Medical Publishing House, 2002:160.
  10. 10.
    de Gramont A, Tournigand C, André T, et al. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 2007;34(2 Suppl 1):S37–40.PubMedCrossRef
  11. 11.
    Wu Y, Luo L, Liu JP, et al. Herbal medicine for relapse and metastasis in patients operated for colorectal cancer. Cochrane Database of Systematic Reviews 2006; Issue 4. Art. No. CD006270.
  12. 12.
    Luo L, Yang YF, Li PH, et al. Cohort study on Fuzheng capsule and Quxie capsule in reducing relapse and metastasis of cancer in patients with stage II and III colorectal cancer after operation. Chin J Integr Tradit West Med (Chin) 2006; 26(8):677–680.
  13. 13.
    Ji JF. Molecular biology foundation of hepatic metastasis from colorectal cancer J Pract Oncol (Chin) 2003;18(2):84–87.
  14. 14.
    Boedefeld WM 2nd, Bland KI, Heslin MJ. Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann Surg Oncol 2003;10:839–851.PubMedCrossRef
  15. 15.
    Rudmik LR, Magliocco AM. Molecular mechanism of hepatic metastasis in colorectal cancer. J Surg Oncol 2005;92:347–359.PubMedCrossRef

Plaats een reactie ...

Reageer op "Chinese Kruiden - TCM alleen of aanvullend op westerse aanpak van darmkanker stadium II en III verminderen kans op recidief met 39 procent op 5-jaars meting in vergelijking met alleen westerse aanpak van chemo en bestraling"


Gerelateerde artikelen
 

Gerelateerde artikelen

TCM - Traditionele Chinese >> ShenQi FuZheng Injectie aanvullend >> TCM - Traditionele Chinese >> Chinese Kruiden - TCM alleen >> Chinese kruiden - Shenqui >> Goshajinkigan - Japans kruidenmengsel >> Chinese kruiden: Injecties >>